Bio-Techne Corp (TECH) Investor Relations Documents

Bio-Techne Corp (TECH) investor relations documents from the company's IR site: 3 presentations, 37 press releases; latest deck 2026-01-01. Read in-app with summaries. First-party data.

View Presentation: Bio-Techne is a life sciences company with $1.2B in FY2025 revenue, focusing on protein sciences, diagnostics, and spatial biology for advanced therapeutics.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-09-01Press releaseBio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
2026-08-13Press releaseBio-Techne Corrects Dividend Announcement
2026-08-12Press releaseBio-Techne Declares Dividend
2026-08-12Press releaseBio-Techne Releases Fourth Quarter Fiscal 2026 Results
2026-07-08Press releaseBio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
2026-06-25Press releaseMerck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sci
2026-06-04Press releaseBio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
2026-05-06Press releaseBio-Techne Declares Dividend
2026-05-06Press releaseBio-Techne Releases Third Quarter Fiscal 2026 Results
2026-05-06Press releaseEarnings Release
2026-05-06Press releasePDF: Bio-Techne Releases Third Quarter Fiscal 2026 Results
2026-05-06Press releasePDF
2026-05-04Press releaseBio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference
2026-04-16Press releaseBio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarit
2026-04-14Press releaseBio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
2026-03-25Press releaseBio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
2026-02-24Press releaseBio-Techne to Present at Upcoming Investor Conferences
2026-02-16Press releaseBio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for Euro
2026-02-11Press releaseBio-Techne Announces Changes to its Leadership Team
2026-02-04Press releaseBio-Techne Declares Dividend
2026-02-04Press releaseBio-Techne Releases Second Quarter Fiscal 2026 Results
2026-02-04Press releaseEarnings Release
2026-02-04Press releasePDF: Bio-Techne Releases Second Quarter Fiscal 2026 Results
2026-02-02Press releaseBio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
2026-01-28Press releaseBio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurologi
2026-01-20Press releaseBio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
2026-01-01PresentationView Presentation
2025-11-05Press releasePDF: Bio-Techne Releases First Quarter Fiscal 2026 Results
2025-08-06Press releaseEarnings Release
2025-08-06Press releasePDF: Bio-Techne Releases Fourth Quarter Fiscal 2025 Results
2025-06-30Press releaseEarnings Release
2025-06-03PresentationPresentation
2025-05-07Press releasePDF: BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
2025-02-05Press releaseEarnings Release
2025-02-05Press releasePDF: Bio-Techne Releases Second Quarter Fiscal 2025 Results
2024-10-30Press releaseHTML
2024-10-30Press releasePDF: BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
2024-08-07Press releasePDF: BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
2024-06-04PresentationPresentation
2024-05-01Press releaseHTML

TECH overview · TECH earnings · TECH financials · TECH KPIs · TECH documents · TECH ownership · TECH peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.